IDYA logo

IDYA
Ideaya Biosciences Inc

1,320
Mkt Cap
$2.67B
Volume
693,957.00
52W High
$39.28
52W Low
$13.45
PE Ratio
-23.37
IDYA Fundamentals
Price
$30.46
Prev Close
$32.09
Open
$31.90
50D MA
$33.12
Beta
1.16
Avg. Volume
853,708.30
EPS (Annual)
-$1.28
P/B
2.61
Rev/Employee
$1.51M
$2,447.46
Loading...
Loading...
News
all
press releases
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...
PR Newswire·3d ago
News Placeholder
More News
News Placeholder
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1% - Here's Why
IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 6.1% - What's Next...
MarketBeat·6d ago
News Placeholder
IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA)
IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the target of unusually large options trading on Monday. Investors purchased 9,704 put options on the stock. This is an increase of 1,197% compared to the typical daily volume of 748 put options...
MarketBeat·6d ago
News Placeholder
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial IDEAYA Biosciences Upcoming Investor Relations Events and...
PR Newswire·7d ago
News Placeholder
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting...
PR Newswire·12d ago
News Placeholder
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seventeen research firms that are covering the stock, MarketBeat.com reports...
MarketBeat·12d ago
News Placeholder
IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP
Cinctive Capital Management LP increased its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 193.9% in the 3rd quarter, according to the company in its most recent Form...
MarketBeat·13d ago
News Placeholder
Iron Triangle Partners LP Makes New Investment in IDEAYA Biosciences, Inc. $IDYA
Iron Triangle Partners LP purchased a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·14d ago
News Placeholder
IDEAYA Biosciences, Inc. $IDYA Position Increased by Baker BROS. Advisors LP
Baker BROS. Advisors LP grew its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 54.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·15d ago
News Placeholder
42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd
WINTON GROUP Ltd bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities...
MarketBeat·18d ago
<
1
2
...
>

Latest IDYA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.